Randomized Controlled Study Comparing Reduced Calcineurin Inhibitors Exposure Versus Standard Cyclosporine-Based Immunosuppression
- 27 September 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 84 (6), 706-714
- https://doi.org/10.1097/01.tp.0000282872.17024.b7
Abstract
Immunosuppressive regimens based on low doses of cyclosporine A (CsA) or tacrolimus (TAC) may improve short-term outcome after kidney transplantation (KT), but the optimal immunosuppressive protocol is currently unknown.This study compared the 24-month efficacy and safety of two immunosuppressive regimens using reduced calcineurin inhibitors (CNIs) exposure with standard dosage of CsA in 240 patients who were randomized into three groups: group A (n=80): Thymoglobulin, CsA (4 mg/kg twice daily) plus azathioprine (1.5 mg/kg once daily); group B (n=80): basiliximab, CsA (2 mg/kg/ twice daily) plus mycophenolate mofetil (MMF; 1 g twice daily); and group C (n=80): basiliximab, TAC (0.05 mg/kg/ twice daily) plus MMF (1 g twice daily). Steroid administration was identical for all groups.A significantly better creatinine clearance at 12 months, estimated by Cockcroft-Gault (57+/-12, 65.2+/-20, 73.5+/-27 ml/min, P=0.044), the Jelliffe-2 (51.5+/-16, 56+/-19, 59.4+/-19 ml/min/1.73 m2, P=0.041) and the Modification of Diet in Renal Disease equations (53+/-17, 58.5+/-20, 61.6+/-22 ml/min/1.73 m2, P=0.035), was observed in group C compared with group A. No significant differences were observed between groups B and C. The incidence of biopsy-proven acute rejection was similar between groups (15%, 13.8%, and 16.3%). In addition, patient and graft survival at 24 months were not different between groups. Adverse effects were similar among groups, but cytomegalovirus infections was significantly higher in group A (41% vs. 20% vs. 25%; P=0.008).Immunosuppressive regimens with reduced CNI exposure provide similar preservation of renal function compared with standard dose of CsA after KT and do not lead to underimmunosuppression.This publication has 20 references indexed in Scilit:
- Current and Evolving Immunosuppressive Regimens in Kidney TransplantationAmerican Journal of Kidney Diseases, 2006
- Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2005
- A Randomized Controlled Trial of Cyclosporine Withdrawal in Renal-Transplant Recipients: 15-Year ResultsTransplantation, 2004
- Performance of Different Prediction Equations for Estimating Renal Function in Kidney TransplantationAmerican Journal of Transplantation, 2004
- Long-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine WithdrawalJournal of the American Society of Nephrology, 2004
- The Natural History of Chronic Allograft NephropathyThe New England Journal of Medicine, 2003
- CYTOMEGALOVIRUS DISEASE IS NOT A MAJOR RISK FACTOR FOR ISCHEMIC HEART DISEASE AFTER RENAL TRANSPLANTATION1Transplantation, 2001
- Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathyKidney International, 2001
- A RANDOMIZED, DOUBLE-BLINDED COMPARISON OF THYMOGLOBULIN VERSUS ATGAM FOR INDUCTION IMMUNOSUPPRESSIVE THERAPY IN ADULT RENAL TRANSPLANT RECIPIENTS1,2Transplantation, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999